Status:
COMPLETED
Impact of HIV and Its Treatment on Reverse Cholesterol Transport
Lead Sponsor:
The Alfred
Collaborating Sponsors:
National Health and Medical Research Council, Australia
Conditions:
HIV Infections
Eligibility:
MALE
18+ years
Brief Summary
To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male patients with HIV infection (3 groups of 50 patients each)
- HIV infected patients, naïve to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months)
- HIV-infected patients, PI naïve, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen)
- HIV-infected patients naïve to ARV therapy, initiating NNRTI-containing regimen
- Exclusion criteria
- Treatment with any form of lipid lowering drugs, including fish oils.
- Body Mass Index greater than 27.
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00168233
Start Date
June 1 2005
End Date
March 1 2011
Last Update
January 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Hospital and Baker Heart Research Institute
Melbourne, Victoria, Australia, 3004